EMEA-000694-PIP04-18

Key facts

Invented name
Forxiga
Active substance
dapagliflozin
Therapeutic area
Uro-nephrology
Decision number
P/0373/2018
PIP number
EMEA-000694-PIP04-18
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Treatment of chronic kidney disease
Route(s) of administration
Oral use
Contact for public enquiries
AstraZeneca AB

Tel. +44 (0)1625 230700
E-mail: paediatrics@astrazeneca.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating